News

EMUC17: Using biomarkers in decision-making for RCC treatment

Renal cell carcinomas are among the most lethal in urological malignancies prompting doctors to search for tools such as biomarkers and other molecular techniques to distinguish aggressive diseases. With new research outcomes, physicians are hopeful that diagnosis and therapy...

EMUC16: National cancer prevention plans need a boost

National cancer plans, which are vital for an effective pan-European cancer care programme, should look closer at prevention, rehabilitation and survivorship issues, according to a public healthcare expert who spoke at the 8th European Multidisciplinary Meeting on Urological Cancers...

EMUC16: Re-thinking active surveillance strategies in PCa

With the emergence of more precise imaging and new results from genomic investigations, onco-urology experts are challenging standard medical strategies and are re-thinking their treatment regimens to achieve better patient care. At the concluding session of the 8th European...

EMUC16: Kidney cancer — from diagnosis to progression

Improving diagnosis and mapping out optimal treatment strategies for kidney cancer patients topped the second-day agenda of the 8th European Meeting on Urological Cancers (EMUC16) in Milan, Italy. The fourth plenary session focused on the challenges in kidney cancer...

EMUC16: Imaging and the treatment landscape for recurrent PCa

Current and prospective treatment strategies that employ image-guided approaches for prostate cancer recurrences were examined with experts exploring options in radiotherapy, surgery and chemotherapy. Speakers Steven Joniau (BE), Barbara Jereczek-Fossa (IT), George Thalmann (CH) and Cora Sternberg (IT) presented...

EMUC16: Experts tackle combined therapies in prostate cancer

Systemic treatments and optimizing various forms of therapies in high-risk and metastatic forms of prostate cancer were examined at the first-day plenary session of the 8th European Meeting on Urological Cancers (EMUC16) which opened today in Milan, Italy. With...

Indolent cancers: The fine art of sophisticated pathology

Identifying patients with indolent cancers from those with aggressive disease are one of the many challenges faced by many doctors. Thus, the least visible specialist such as a pathologist could actually be holding the crucial key in diagnostic and...